MedTrace Logo

Therapeutic Strategy Associated With bDMARDs or tsDMARDs in Rheumatoid Arthritis and Psoriatic Arthritis

NCT05082805 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2021-10-19

No results posted yet for this study

Summary

This is a longitudinal, observational, prospective, multicentre study conducted in France, among a representative sample of rheumatology doctors.

The aim of this study is to describe in real life the therapeutic strategy when faced with a patient with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) who requires initiation of treatment with biotherapy or targeted therapy. The evolution of the disease and the possible therapeutic adaptations will then be followed for 2 years.

Conditions

Sponsors & Collaborators

  • Nordic Pharma SAS

    lead INDUSTRY

Principal Investigators

  • Hélène HERMAN-DEMARS, MD · Nordic Pharma

  • René Marc FLIPO, Prof · CHRU LILLE

  • Cécile GAUJOUX-VIALA, Dr · CHU Nîmes

  • Emmanuelle DERNIS, Dr · CH Le Mans

  • Éric SENBEL, Dr · Marseille

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-25
Primary Completion
2021-12-31
Completion
2022-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05082805 on ClinicalTrials.gov